Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353905 | 1.00 | PARP1 (0.42) | PARP1NPC1RAB9AHTTESR2 | |
| SCHEMBL15710544 | 0.85 | PARP1 (0.44) | PARP1NPC1RAB9AKDM4EPDPK1 | |
| SCHEMBL30353912 | 0.85 | PARP1 (0.44) | PARP1NPC1RAB9AKDM4EPDPK1 | |
| SCHEMBL16747757 | 0.85 | KDM4E (0.39) | PARP1NPC1RAB9AHTTKDM4E | |
| SCHEMBL30353899 | 0.84 | NPC1 (0.44) | PARP1NPC1RAB9AHTTESR2 | |
| SCHEMBL3187133 | 0.84 | NPC1 (0.44) | PARP1NPC1RAB9AHTTESR2 | |
| Hydrochloric Acid SCHEMBL28100847 | 0.84 | PARP1 (0.43) | PARP1NPC1RAB9AKDM4EPDPK1 | |
| SCHEMBL31204526 | 0.82 | HTT (0.42) | PARP1NPC1RAB9AHTTESR2 | |
| SCHEMBL6910259 | 0.81 | NPC1 (0.41) | PARP1NPC1RAB9AHTTESR2 | |
| SCHEMBL3203285 | 0.81 | PARP1 (0.41) | PARP1RAB9AKDM4EPDPK1IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110573505-B | C 5 -anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-3615522-B1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2020-11-10 | — | — | US | disclosed |
| EP-3615522-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca (SE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573505-A | C5-anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20190263787-A1 | C5-anilinoquinazoline Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-08-29 | — | — | US | disclosed |
| US-10273227-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-04-30 | — | — | US | disclosed |
| WO-2018197642-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | WO | disclosed |
| US-20180312490-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263787-A1 | C5-anilinoquinazoline Compounds and Their Use in Treating Cancer | KIT, C5, C9 | PARP1 158/4885NPC1 1576/4885RAB9A 617/4885 |
| US-20180312490-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | KIT, C5, C9 | PARP1 158/4885NPC1 1576/4885RAB9A 617/4885 |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | KIT, C5, C9 | PARP1 158/4885NPC1 1576/4885RAB9A 617/4885 |
| US-10273227-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | KIT, C5, C9 | PARP1 158/4885NPC1 1576/4885RAB9A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.